You are here

Article Text

Article menu

Download PDFPDF

Electronic pages
Correspondence response
Response to: ‘Could abatacept directly target expanded plasmablasts in IgG4-related disease?’ by Alegria et al
Free
  1. Motohisa Yamamoto1,
  2. Hiroki Takahashi1,
  3. Kenichi Takano2,
  4. Tetsuo Himi2,
  5. Hiroshi Nakase3
  1. 1Department of Rheumatology, Sapporo Medical University School of Medicine, Sapporo, Japan
  2. 2Department of Otolaryngology, Sapporo Medical University School of Medicine, Sapporo, Japan
  3. 3Department of Gastroenterology, Sapporo Medical University School of Medicine, Sapporo, Japan
  1. Correspondence to Dr Motohisa Yamamoto, Department of Rheumatology, Sapporo Medical University School of Medicine, South 1-West 16, Chuo-ku, Sapporo, Hokkaido 060-8543, Japan; mocha{at}cocoa.plala.or.jp

https://doi.org/10.1136/annrheumdis-2016-210403

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    We thank Alegria et al1 for their response to our letter.2 IgG4-related disease (IgG4-RD) is a chronic fibroinflammatory disorder that can involve various organs, but its origin remains unknown.3 Although elevated levels of circulating plasmablasts are observed in the active phase of IgG4-RD4 ,5 the pathogenesis cannot be fully explained by plasmablasts alone. In our report,2 we described a patient treated with abatacept who presented with complete depletion of circulating CD19+ cells at the …

    View Full Text

    Linked Articles